$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of common side effects and possible health risks of Almonertinib
2026-02-01 22:25:32
Check Details
Whether Leborexan (Daveco) can be taken for a long time and the safety assessment of long-term use
2026-02-01 22:25:32
Check Details
The targeted mechanism and scientific principles of Mavakatai (Mafantuo) in the treatment of cardiac hypertrophy
2026-02-01 22:25:32
Check Details
Detailed interpretation of the key contents of the official instruction manual of Tenofovir Alafenamide Fumarate Tablets (Vemlidy)
2026-02-01 22:25:32
Check Details
Comparison of the effects of vorasidenib-VORANIGO and vorasidenib in the treatment of glioma
2026-02-01 22:25:32
Check Details
Instructions on contraindications of eflornithine (IWILFIN) and those for whom its use is not recommended
2026-02-01 22:25:32
Check Details
Analysis of the main functions and clinical therapeutic effects of odexibat (Belvi)
2026-02-01 22:25:32
Check Details
Donepezil (Aricept) imported drug name and comparison of differences with domestic versions
2026-02-01 22:25:32
Check Details
Analysis of possible causes of skin changes after taking Fidaxomicin for six days
2026-02-01 22:25:32
Check Details
Standard usage and dosage of ponatinib and dosage adjustment recommendations for different patients
2026-02-01 22:25:32
Check Details
Why Trelagliptin cannot be taken casually and analysis of possible risks caused by abuse
2026-02-01 22:25:32
Check Details
Possible risks and countermeasures after sudden discontinuation of Inalisate (Iheli)
2026-02-01 22:25:32
Check Details
1
2
...
1913
1914
1915
1916
1917
1918
1919
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide